Overview
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 66 days late).
- 202514/07/2026
- 202405/07/2025
- 202312/07/2024
- 202212/07/2023
- 202119/09/2022
- 202007/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Authorized Representatives
Manner of representation
The company is represented without limitation by the President of the Management Board independently or by two members of the management board jointly; however, each member of the management board represents the company independently in matters of ordinary management up to the amount of 1,000,000 złoty.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Enrav Fundacja Rodzinna | 1,256 | $16,963.80 | 62.8% |
Med Management Scsp | 310 | $4,186.93 | 15.5% |
Jarosław Piotr Molędaage 49 | 434 | $5,861.70 | 21.7% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2017-11-01.
64 1600 1462 1742 6895 2000 0008- 21 1600 1462 1742 6895 2000 0006
06 1140 2004 0000 3512 0777 8923
Debt
No entries in the National Debtors Register (KRZ).
Public aid
5 public aid cases recorded, with a total value of $5,830,639.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 19, 2025 | Aid for research and development projects: industrial research | $2.3M$2,253,819 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| May 19, 2025 | Aid for research and development projects: experimental development | $918K$917,969 | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jan 21, 2022 | Aid for research and development projects: experimental development | $2.3M$2,322,675 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-07-01 | Product innovation in the form of a single-use safety injection needle with variable operating modes, innovative on a global scale, together with a novel IoT-based technological manufacturing process. | $3.2M$3,171,788 | European Funds for a Modern Economy | |
| 2022-01-01 | Development of a dedicated manufacturing technology for an innovative product: a universal safety needle for different types of syringes, ensuring unprecedented user safety (from unpacking through filling and injection to disposal) and minimal dead space to reduce product loss | $2.7M$2,658,850 | Operational Programme Smart Growth |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| American Way Polska Miłkowskisp. k. | $1,893,749.17 | americanwaypolska.pl | ||
| Brandexsp. z o.o. | $1,958,619.75 | brandex.pl | ||
| PUBE Globalsp. z o.o. | $1,777,827.09 | pubeglobal.com | ||
| Tricopat Globalsp. z o.o. | $1,772,824.41 | tricopatglobal.com | ||
| Novicaresp. z o.o. | $1,512,398.66 | novicare.pl | ||
| Dental Solutionssp. z o.o. | $611,683.37 | dentalsolutions.pl | ||
| Beauty Care Solutionsp. z o.o. | $391,209.94 | ohhira.pl | ||
| Aimedicalsp. z o.o. | $240,059.72 | aimedical.pl | ||
| Vorwarts Pharmasp. z o.o. | $210,138.62 | vorwartspharma.pl | ||
| Black & Whitesp. z o.o. | $154,866.36 | polonus.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-03 | Share capital increase (20,250.00 PLN → 100,000.00 PLN) | |
| 2025-10-03 | Switch to PKD 2025 (5 PKD 2007 codes → 5 PKD 2025 codes) | |
| 2023-05-09 | Share capital increase (5,000.00 PLN → 20,250.00 PLN) | |
| 2023-05-09 | PKD change (Removed: 9 codes; Added: 5 codes) | |
| 2017-08-11 | Entered in the register |
FAQ
Last updated: 2026-07-17